MCID: PLC008
MIFTS: 50

Placenta Disease

Categories: Fetal diseases, Rare diseases

Aliases & Classifications for Placenta Disease

MalaCards integrated aliases for Placenta Disease:

Name: Placenta Disease 12 15 17
Pregnancy Complications 43 71
Placenta Disorder 74 52
Placenta Diseases 52 43
Placenta Disorders 71

Classifications:



External Ids:

Disease Ontology 12 DOID:780
ICD9CM 34 646.9
SNOMED-CT 67 125586008 173300003
ICD10 32 O43
UMLS 71 C0032045 C0032962 C0151864 more

Summaries for Placenta Disease

Disease Ontology : 12 A uterine disease that is located in the placenta.

MalaCards based summary : Placenta Disease, also known as pregnancy complications, is related to antiphospholipid syndrome and placenta praevia, and has symptoms including hyperemesis gravidarum, morning sickness and late pregnancy bleeding. An important gene associated with Placenta Disease is PAPPA (Pappalysin 1), and among its related pathways/superpathways is Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Sulfanilamide and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include placenta, ovary and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 A placental disease is any disease, disorder, or pathology of the... more...

Related Diseases for Placenta Disease

Diseases related to Placenta Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 861)
# Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 33.1 SERPINC1 PGF MTHFR F5 F3 APOH
2 placenta praevia 32.6 PGF PAPPA OXT
3 placenta accreta 32.6 PGF PAPPA OXT
4 placental abruption 32.5 SERPINC1 PGF PAPPA MTHFR F5 APOH
5 oligohydramnios 32.4 PGF PAPPA OXT MIR517A CGA AFP
6 placental insufficiency 32.3 SERPINC1 PGF PAPPA MIR520A MIR517A F3
7 eclampsia 31.9 SERPINC1 PGF PAPPA OXT MTHFR APOH
8 severe pre-eclampsia 31.6 SERPINC1 PGF PAPPA MIR517A F5 APOH
9 pre-eclampsia 31.4 SERPINC1 PGF PAPPA OXT MTHFR F5
10 thrombophilia 31.4 SERPINC1 MTHFR F5 F3 APOH ANXA5
11 purpura 31.4 SERPINC1 F3 APOH
12 hellp syndrome 31.3 SERPINC1 PGF MTHFR HADHA F5 F3
13 ectopic pregnancy 31.1 PGF PAPPA CGB7 CGB5 CGB3 CGA
14 disseminated intravascular coagulation 31.1 SERPINC1 F5 F3
15 thrombocytopenia 31.1 SERPINC1 MTHFR F5 F3 APOH ANXA5
16 vascular disease 31.0 SERPINC1 MTHFR F5 F3 APOH
17 ovarian hyperstimulation syndrome 31.0 F5 CGB5 CGA
18 gestational trophoblastic neoplasm 31.0 PGF CGB5 AFP
19 hydatidiform mole, recurrent, 1 31.0 CGB5 CGB3 CGA
20 gastroschisis 31.0 MTHFR F5 AFP
21 anencephaly 31.0 MTHFR CGB5 AFP
22 chromosomal triplication 31.0 PAPPA CGB7 CGB3 AFP
23 pulmonary embolism 30.9 SERPINC1 MTHFR F5 F3 APOH
24 thrombophilia due to thrombin defect 30.9 SERPINC1 MTHFR F5 F3 APOH
25 thrombotic thrombocytopenic purpura 30.8 SERPINC1 F3 APOH
26 bilirubin metabolic disorder 30.8 OXT F3 AFP
27 homocysteinemia 30.8 SERPINC1 MTHFR F5 APOH
28 teratoma 30.7 CGB7 CGB5 CGB3 CGA AFP
29 thrombophilia due to activated protein c resistance 30.7 SERPINC1 MTHFR F5 F3 APOH
30 thrombosis 30.6 SERPINC1 MTHFR F5 F3 APOH ANXA5
31 hypertension, essential 30.6 SERPINC1 PGF PAPPA OXT MTHFR MIR520A
32 triploidy 30.6 PAPPA CGB7 CGA AFP
33 mild pre-eclampsia 30.6 PGF PAPPA OXT MIR517A
34 patau syndrome 30.6 PGF PAPPA AFP
35 choriocarcinoma 30.6 CGB7 CGB5 CGB3 CGA
36 down syndrome 30.6 PGF PAPPA MTHFR CGB7 CGB5 CGB3
37 thrombophlebitis 30.6 SERPINC1 MTHFR F5 F3 APOH
38 protein s deficiency 30.6 SERPINC1 MTHFR F5 F3 APOH
39 endodermal sinus tumor 30.6 MIR371A CGB3 AFP
40 varicose veins 30.5 SERPINC1 MTHFR F5 COL3A1
41 sacrococcygeal teratoma 30.5 CGB7 CGA AFP
42 portal vein thrombosis 30.4 SERPINC1 MTHFR F5 APOH AFP
43 pregnancy loss, recurrent 1 30.3 MTHFR F5 APOH
44 prothrombin deficiency, congenital 30.3 SERPINC1 F5 APOH
45 hepatic coma 30.3 SERPINC1 F3 AFP
46 neonatal anemia 30.2 PGF PAPPA
47 esophageal varix 30.2 SERPINC1 F3 AFP
48 papilledema 30.2 SERPINC1 F3 APOH
49 orofaciodigital syndrome viii 30.2 PAPPA CGA AFP
50 factor xiii deficiency 30.2 SERPINC1 F5 F3

Graphical network of the top 20 diseases related to Placenta Disease:



Diseases related to Placenta Disease

Symptoms & Phenotypes for Placenta Disease

UMLS symptoms related to Placenta Disease:


hyperemesis gravidarum, morning sickness, late pregnancy bleeding, maternal fever, intrapartum fever

GenomeRNAi Phenotypes related to Placenta Disease according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.77 PAPPA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.77 CGB5 CGB7
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 9.77 MTHFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 MTHFR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.77 CGB5 CGB7
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.77 MTHFR
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.77 PAPPA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.77 CGB5 CGB7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.77 PAPPA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.77 PAPPA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.77 MTHFR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.77 CGB5 CGB7
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.77 CGB5 CGB7
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 9.77 PAPPA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.77 MTHFR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 MTHFR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.77 MTHFR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.77 PAPPA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.77 MTHFR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 MTHFR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.77 CGB5 CGB7 MTHFR

Drugs & Therapeutics for Placenta Disease

Drugs for Placenta Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulfanilamide Approved Phase 4 63-74-1 5333
2
Remifentanil Approved Phase 4 132875-61-7 60815
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
6
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
7
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
8
Tranexamic Acid Approved Phase 4 1197-18-8 5526
9
Clarithromycin Approved Phase 4 81103-11-9 84029
10
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Enoxaparin Approved Phase 4 9005-49-6 772
13
Dalteparin Approved Phase 4 9005-49-6
14
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
15
Metronidazole Approved Phase 4 443-48-1 4173
16
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
17
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
18
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
19
Fibrinolysin Investigational Phase 4 9004-09-5
20 Hypoglycemic Agents Phase 4
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Anesthetics, Intravenous Phase 4
24 Antacids Phase 4
25 Anti-Ulcer Agents Phase 4
26 Contraceptives, Postcoital Phase 4
27 Ergocalciferols Phase 4
28 Calcium, Dietary Phase 4
29 Vitamin D2 Phase 4
30 Acidophilus Phase 4
31 Sulfalene Phase 4
32 Bifidobacterium Phase 4
33 Ferric Oxide, Saccharated Phase 4
34 Ferric Compounds Phase 4
35 Antibodies Phase 4
36 Fat Emulsions, Intravenous Phase 4
37 Parenteral Nutrition Solutions Phase 4
38 Soy Bean Phase 4
39 Pharmaceutical Solutions Phase 4
40 Soybean oil, phospholipid emulsion Phase 4
41 Antibodies, Antiphospholipid Phase 4
42 Immunoglobulins Phase 4
43 Hemostatics Phase 4
44 Antifibrinolytic Agents Phase 4
45 Coagulants Phase 4
46 Hormone Antagonists Phase 4
47 Hormones Phase 4
48 Contraceptive Agents Phase 4
49 Fibrinolytic Agents Phase 4
50 Anticoagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 425)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
2 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
3 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
4 Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW Completed NCT00190294 Phase 4 MIFEPRISTONE 200 mg and misoprostol 400 µg
5 Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels Completed NCT01337791 Phase 4 Telbivudine treatment
6 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
7 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
8 Vitamin D Dose-response Study Throughout Pregnancy and Lactation Completed NCT01112891 Phase 4 Vitamin D;Vitamin D3;Vitamin D
9 The POP-study: Effect of Probiotics on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn - a Randomized, Double-blind Placebo Controlled Trial With Vivomixx® Completed NCT02508844 Phase 4
10 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
11 Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome? Recruiting NCT04274803 Phase 4 Intralipid, 20% Intravenous Emulsion;Conventional therapy of antiphospholipis syndrome
12 The Clinical Carbetocin Myocardium Trial Part 2 Recruiting NCT03899961 Phase 4 Oxytocin;Carbetocin
13 Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk Recruiting NCT02797119 Phase 4 tranexamic acid 1 g (TA1);tranexamic acid 0.5 g (TA1/2);Saline Solution (TA0)
14 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Recruiting NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
15 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Enrolling by invitation NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
16 Effect of Low-Molecular-Weight-Heparin (LMWH) on Pregnancy Outcome in Women With Multiple Failures of IVF-ET Not yet recruiting NCT03701750 Phase 4 Low Molecular Weight Heparin (enoxaparin sodium)
17 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
18 Prolonged Treatment for Infected Abortion After Hospital Discharge. Terminated NCT00376493 Phase 4 metronidazole and doxycycline
19 Vitamin D During In Vitro Fertilisation (IVF) - A Prospective Randomized Trial Unknown status NCT01019785 Phase 3
20 Low Molecular Weight Heparin for Pregnant Women With Thrombophilia: a Prospective, Randomized, Open Trial Unknown status NCT01019655 Phase 3 Nadroparin calcium
21 METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study Unknown status NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid
22 Does Routine Membrane Sweeping in Uncomplicated Term Pregnancies Increase the Rate of Prelabour Rupture of Membranes Unknown status NCT00294242 Phase 3
23 Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial Unknown status NCT01635426 Phase 2, Phase 3 Aspirin;Clopidogrel
24 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
25 Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus: A Randomized Controlled Trial Unknown status NCT02838147 Phase 3
26 Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial Completed NCT01388322 Phase 3 Enoxaparin
27 Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00159536 Phase 3 Metformin;Placebo
28 A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy Completed NCT00614445 Phase 3 doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg;Placebo
29 Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT) Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
30 TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women. Completed NCT00967382 Phase 3 dalteparin sodium
31 Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection Completed NCT00197561 Phase 3
32 Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation Completed NCT01735669 Phase 3 Remifentanil;Nitrous Oxide
33 Trial of Vitamins Among Children of HIV-infected Women Completed NCT00197730 Phase 3 Multivitamins - vitamins B complex, C and E;Placebo
34 Impact of Periodontal Therapy on Endothelial Function Completed NCT00681564 Phase 3
35 A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates Completed NCT00006396 Phase 3 Nevirapine;Zidovudine
36 A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) Completed NCT00000751 Phase 3 Anti-HIV Immune Serum Globulin (Human);Globulin, Immune;Zidovudine
37 A Phase III Randomized Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerance of Oral Zidovudine (AZT) in Pregnant HIV Infected Women and Their Infants Completed NCT00000960 Phase 3 Zidovudine
38 A Randomized, Open-Label, Study of Pre-emptive Diclectin® Treatment for Severe Nausea and Vomiting of Pregnancy Completed NCT00293644 Phase 3 Diclectin®
39 Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women? Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
40 Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy Completed NCT00017719 Phase 3 Lamivudine;Lamivudine/Zidovudine;Nelfinavir mesylate;Nevirapine;Zidovudine
41 A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00001135 Phase 3 Nevirapine
42 A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00000942 Phase 3 Nevirapine
43 A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00000869 Phase 3 Nevirapine
44 Feasibility Study of the Measurement of the Placental Perfusion During the First Trimester of Pregnancy by 3D Doppler Echo-angiography With a Contrast Agent Completed NCT02884297 Phase 3 Contrast agent: SonoVue®.
45 Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation Completed NCT01932788 Phase 3 Vitamin D3 4000 IU in gummy form;Placebo gummy vitamin
46 A Randomised Controlled Trial Comparing the Effect of the Faster-acting Insulin Analog - Insulin Fiasp® - Versus Insulin Novorapid® in the Treatment of Women With Type 1 or Type 2 Diabetes During Pregnancy and Lactation. The Copen-fast Trial Recruiting NCT03770767 Phase 3 Faster-acting Aspart insulin Fiasp;Control (insulin Novorapid)
47 Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy Recruiting NCT02932475 Phase 3 Metformin;Placebo
48 Impact of Home-based Oxygen Therapy on Maternal and Fetal Complications, in Pregnant Women With Sickle Cell Disease. A Randomized Multi-center Trial. Recruiting NCT02813850 Phase 3
49 Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin Active, not recruiting NCT00131235 Phase 3 Sulfadoxine-pyrimethamine treatment twice during pregnancy;Sulfadoxine-pyrimethamine at 4-week intervals;Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
50 Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D Active, not recruiting NCT02434380 Phase 3

Search NIH Clinical Center for Placenta Disease

Cochrane evidence based reviews: placenta diseases

Genetic Tests for Placenta Disease

Anatomical Context for Placenta Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Placenta Disease:

19
Placenta

MalaCards organs/tissues related to Placenta Disease:

40
Placenta, Ovary, Testes, Heart, Endothelial, Thyroid, Liver

Publications for Placenta Disease

Articles related to Placenta Disease:

(show top 50) (show all 5516)
# Title Authors PMID Year
1
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 61 54
20363656 2010
2
Full-length adiponectin attenuates insulin signaling and inhibits insulin-stimulated amino Acid transport in human primary trophoblast cells. 61 54
20150288 2010
3
Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions. 54 61
20132984 2010
4
The relationship between unexplained elevated serum markers in triple test, uterine artery Doppler measurements and adverse pregnancy outcome. 54 61
20225773 2010
5
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. 54 61
19556010 2009
6
[Thrombophilia, preeclampsia and other pregnancy complications]. 54 61
20034330 2009
7
Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. 61 54
19232551 2009
8
[Angiogenic factors and their role in pathogenesis and prediction of preeclampsia]. 61 54
19536710 2009
9
Does thrombophilia testing help in the clinical management of patients? 61 54
18710381 2008
10
Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. 61 54
18827058 2008
11
Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. 61 54
18814068 2008
12
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. 54 61
18175241 2008
13
The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. 54 61
18028481 2008
14
Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. 54 61
17720945 2007
15
Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. 54 61
17468256 2007
16
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. 54 61
17302880 2007
17
Acute liver failure in pregnancy associated with maternal MCAD deficiency. 54 61
17186412 2007
18
[Genomic diagnosis of thrombophilia in women: clinical relevance]. 61 54
17279273 2007
19
Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance. 54 61
17081681 2007
20
Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. 61 54
17919116 2007
21
Factor V Leiden, pregnancy complications and adverse outcomes. 61 54
16931620 2006
22
Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. 54 61
16855163 2006
23
[Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]. 61 54
17195354 2006
24
Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. 61 54
16613994 2006
25
Evaluation of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase gene mutations in patients with severe pregnancy complications in northern Finland. 61 54
16514238 2006
26
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. 61 54
16086443 2005
27
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? 54 61
15858960 2005
28
[Impact of inherited thrombophilia on the development of some pregnancy complications]. 54 61
16313049 2005
29
Elevated second-trimester free beta-hCG as an isolated finding and pregnancy outcomes. 61 54
15539871 2004
30
Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. 61 54
15210385 2004
31
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome? 54 61
15099868 2004
32
Maternal serum free beta-hCG levels in uncomplicated pregnancies at the 10th-15th week of gestation and the development of obstetric complications. 54 61
15018435 2004
33
Pronto ThromboRisk--a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia. 54 61
15356875 2004
34
Haemostatic changes in pregnancy. 61 54
15507271 2004
35
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. 54 61
14663836 2003
36
Maternal midtrimester free beta-HCG and AFP serum levels in spontaneous singleton pregnancies complicated by gestational diabetes mellitus, pregnancy-induced hypertension or obstetric cholestasis. 61 54
14691989 2003
37
Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies. 54 61
14672476 2003
38
Characterization of a pseudogene for murine methylenetetrahydrofolate reductase. 54 61
14577615 2003
39
Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. 61 54
14526312 2003
40
Autoimmune disease as a cause of reproductive failure. 61 54
12848445 2003
41
Procoagulant and anticoagulant mechanisms in human placenta. 61 54
12709921 2003
42
[Factor V Leiden mutation and pregnancy complications]. 61 54
14515043 2003
43
Multiple transcription start sites and alternative splicing in the methylenetetrahydrofolate reductase gene result in two enzyme isoforms. 54 61
12370778 2002
44
[Genetic mutations, acquired coagulation system disorders and obstetric pathology. Personal experience]. 54 61
11828266 2002
45
[Effect of thrombophilic factors on thromboembolism and other pregnancy complications]. 61 54
11570192 2001
46
Postnatal screening for thrombophilia in women with severe pregnancy complications. 54 61
11339929 2001
47
Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. 54 61
11295727 2001
48
Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. 61 54
12083967 2001
49
The influence of parity and gravidity on first trimester markers of chromosomal abnormality. 54 61
11038455 2000
50
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. 54 61
11028579 2000

Variations for Placenta Disease

Expression for Placenta Disease

Search GEO for disease gene expression data for Placenta Disease.

Pathways for Placenta Disease

GO Terms for Placenta Disease

Cellular components related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 SERPINC1 PGF PAPPA OXT F5 F3
2 endoplasmic reticulum lumen GO:0005788 9.56 SERPINC1 F5 COL3A1 AFP
3 collagen-containing extracellular matrix GO:0062023 9.55 SERPINC1 F3 COL3A1 APOH ANXA5
4 extracellular space GO:0005615 9.44 SERPINC1 PGF PAPPA OXT F5 F3

Biological processes related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.71 PGF CGB7 CGB5 CGB3
2 cellular protein metabolic process GO:0044267 9.67 SERPINC1 PAPPA F5 AFP
3 platelet degranulation GO:0002576 9.65 F5 APOH ANXA5
4 female pregnancy GO:0007565 9.63 PGF PAPPA OXT
5 blood coagulation GO:0007596 9.62 SERPINC1 F5 F3 ANXA5
6 regulation of blood coagulation GO:0030193 9.43 SERPINC1 APOH
7 hormone-mediated signaling pathway GO:0009755 9.43 CGB7 CGB5 CGB3
8 female gamete generation GO:0007292 9.33 CGB7 CGB5 CGB3
9 peptide hormone processing GO:0016486 9.13 CGB5 CGB3 CGA
10 hemostasis GO:0007599 8.92 SERPINC1 F5 F3 ANXA5

Molecular functions related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.33 F3 APOH ANXA5
2 protease binding GO:0002020 9.13 SERPINC1 F3 COL3A1
3 hormone activity GO:0005179 9.02 OXT CGB7 CGB5 CGB3 CGA

Sources for Placenta Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....